Milestone Pharmaceuticals Inc

$2.16
(as of Jul 7, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Milestone Pharmaceuticals Inc

Stock Price
$2.16
Ticker Symbol
MIST
Exchange
NASDAQ

Industry Information for Milestone Pharmaceuticals Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Milestone Pharmaceuticals Inc

Website
https://www.milestonepharma.com
Country
USA
Full Time Employees
33

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

Fundamentals for Milestone Pharmaceuticals Inc

Market Capitalization
$103,720,744
EBITDA
$-52,045,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-0.77
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
53,464,300
Percent Owned by Insiders
4.71%
Percent Owned by Institutions
22.25%
52-Week High
52-Week Low

Technical Indicators for Milestone Pharmaceuticals Inc

50-Day Moving Average
200-Day Moving Average
RSI
74.51
ATR
0.11

Analyst Ratings for Milestone Pharmaceuticals Inc

Strong Buy
0
Buy
2
Hold
2
Sell
0
Strong Sell
0

News About Milestone Pharmaceuticals Inc

Jun 16, 2025, 8:36 AM EST
(RTTNews) - Milestone Pharmaceuticals Inc. See more.
Jun 16, 2025, 8:09 AM EST
MONTREAL/CHARLOTTE - Milestone Pharmaceuticals Inc. See more.
May 14, 2025, 7:04 AM EST
Resolution of CRL Manufacturing issues in progress - Type A meeting requested See more.
Mar 28, 2025, 7:00 AM EST
CRL focused on CMC; no clinical issues relating to etripamil raised See more.